Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Fair Value Of Equity Method Investment In Gannet Bio Chem Received In Exchange For Sale Of Huntsville Manufacturing Facility

Fair Value Of Equity Method Investment In Gannet Bio Chem Received In Exchange For Sale Of Huntsville Manufacturing Facility at other companies

EFC
Ellington Financial Inc.EFC
$349.72M+30.0%
Mosaic logo
MosaicMOS
$134.55M—
Vestis logo
VestisVSTS
$0—
DJT
Trump Media & Technology GroupDJT
$13.92M—
AXT
AXTAXTI
$0—
Beam Therapeutics logo
Beam TherapeuticsBEAM
$63.79M—

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept nktr:FairValueOfEquityMethodInvestmentInGannetBioChemReceivedInExchangeForSaleOfHuntsvilleManufacturingFacility.

The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility?
Nektar Therapeutics (NKTR) reported fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility of $0 in Q4 2025.
How has Nektar Therapeutics's fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility changed year-over-year?
Nektar Therapeutics's fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility decreased by 100.0% year-over-year, from $3.05M to $0.
What does fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility mean?
This metric represents the non-cash value assigned to an equity interest received as consideration for the divestiture of manufacturing infrastructure or real estate assets. It reflects the strategic shift of capital from tangible operating assets into a minority ownership stake in a third-party entity. Investors use this to assess the valuation of non-monetary proceeds and the potential long-term strategic alignment with the investee.